Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FGEN 
FibroGen Inc (FGEN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: FGEN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $43
1 Year Target Price $43
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 7.78% | Avg. Invested days 27 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.65M USD | Price to earnings Ratio - | 1Y Target Price 43 |
Price to earnings Ratio - | 1Y Target Price 43 | ||
Volume (30-day avg) 2 | Beta 0.77 | 52 Weeks Range 4.50 - 21.94 | Updated Date 09/15/2025 |
52 Weeks Range 4.50 - 21.94 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -21.61 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.12% | Operating Margin (TTM) -864.91% |
Management Effectiveness
Return on Assets (TTM) -16.4% | Return on Equity (TTM) -1015.79% |
Valuation
Trailing PE - | Forward PE 61.35 | Enterprise Value 99014104 | Price to Sales(TTM) 6.62 |
Enterprise Value 99014104 | Price to Sales(TTM) 6.62 | ||
Enterprise Value to Revenue 13.48 | Enterprise Value to EBITDA -0.17 | Shares Outstanding 4043900 | Shares Floating 3628227 |
Shares Outstanding 4043900 | Shares Floating 3628227 | ||
Percent Insiders 1.57 | Percent Institutions 26.51 |
Upturn AI SWOT
FibroGen Inc
Company Overview
History and Background
FibroGen, Inc. is a biopharmaceutical company founded in 1993. Initially focused on connective tissue growth factor (CTGF), it has evolved to develop therapies for anemia, fibrosis, and cancer. Early research centered on collagen biosynthesis. A significant milestone was the development and approval of roxadustat for anemia in various countries.
Core Business Areas
- Anemia: Development and commercialization of roxadustat, an oral HIF-PHI inhibitor for the treatment of anemia associated with chronic kidney disease (CKD) and other conditions. Seeking regulatory approvals in the US and expanding globally.
- Fibrosis: Research and development of pamrevlumab, an anti-CTGF antibody, for the treatment of idiopathic pulmonary fibrosis (IPF), Duchenne muscular dystrophy (DMD), and pancreatic cancer. Ongoing clinical trials to demonstrate efficacy.
- Research and Development: Discovery and development of novel therapeutic candidates in areas such as oncology and other unmet medical needs.
Leadership and Structure
The leadership team includes Enrique Conterno (CEO). The organizational structure consists of research and development, clinical operations, regulatory affairs, and commercial functions.
Top Products and Market Share
Key Offerings
- Roxadustat (Evrenzo): An oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) for treating anemia in patients with chronic kidney disease. Currently approved in China, Japan, Europe, and other regions. Market share varies by region. Competitors include injectable erythropoiesis-stimulating agents (ESAs) like epoetin alfa (Amgen's Epogen/Procrit) and darbepoetin alfa (Amgen's Aranesp), as well as other emerging HIF-PHI inhibitors such as Akebia Therapeutics' vadadustat (Auryxia).
- Pamrevlumab: An anti-CTGF (connective tissue growth factor) antibody being developed for idiopathic pulmonary fibrosis (IPF), Duchenne muscular dystrophy (DMD) and pancreatic cancer. No market share yet as it is still in clinical trials. Competitors in IPF include Ofev (nintedanib) by Boehringer Ingelheim and Esbriet (pirfenidone) by Roche/Genentech.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. Significant growth is driven by aging populations, increasing prevalence of chronic diseases, and advances in biotechnology.
Positioning
FibroGen focuses on innovative therapies in areas with unmet medical needs. Its competitive advantages include roxadustat's oral formulation and its pipeline of anti-CTGF antibodies targeting fibrosis and cancer. Roxadustat, if approved in the US, could gain significant market share of the anemia treatment market.
Total Addressable Market (TAM)
The global anemia market is estimated to be in the billions of dollars, with roxadustat targeting a significant portion. The IPF and DMD markets also represent large TAM opportunities for Pamrevlumab. FibroGen is well positioned to capture a share of these markets if its products are successful.
Upturn SWOT Analysis
Strengths
- Novel HIF-PHI technology with roxadustat
- Pipeline of anti-CTGF antibodies
- Partnerships with major pharmaceutical companies
- Experienced management team
Weaknesses
- Roxadustat's regulatory setbacks in the US
- Reliance on partner revenues
- Clinical trial risks and uncertainties
- High R&D expenses
Opportunities
- Roxadustat US approval potential
- Expansion of roxadustat into new indications
- Positive clinical trial results for pamrevlumab
- Strategic collaborations and acquisitions
Threats
- Competition from established therapies
- Regulatory hurdles and delays
- Patent expirations and generic entry
- Unfavorable clinical trial outcomes
Competitors and Market Share
Key Competitors
- AMGN
- AKBA
- BMY
- MRK
Competitive Landscape
FibroGen faces significant competition from established pharmaceutical companies with existing anemia and fibrosis therapies. Its advantages include roxadustat's oral formulation and the potential of pamrevlumab to address unmet needs. However, it must overcome regulatory hurdles and demonstrate clinical efficacy to gain market share. FibroGen needs to look out for any new competing drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by partnership revenues and roxadustat approvals in certain regions.
Future Projections: Future growth depends on roxadustat's US approval and the success of pamrevlumab clinical trials. Analyst estimates vary based on these factors.
Recent Initiatives: Recent initiatives include pursuing US regulatory approval for roxadustat, advancing pamrevlumab clinical trials, and seeking new collaborations.
Summary
FibroGen is a biopharmaceutical company with a focus on anemia and fibrosis. Roxadustat approval in the US is crucial for its growth, while pamrevlumab's clinical trial results will be key. The company faces competition from established therapies and must manage regulatory hurdles. Continued clinical success and strategic partnerships will be essential. FibroGen is currently an average company that needs strong performance to move ahead of the competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- FibroGen Investor Relations
- SEC Filings (10-K, 10-Q)
- Industry Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About FibroGen Inc
Exchange NASDAQ | Headquaters San Francisco, CA, United States | ||
IPO Launch date 2014-11-14 | CEO & Director Mr. Thane Wettig | ||
Sector Healthcare | Industry Biotechnology | Full time employees 225 | Website https://www.fibrogen.com |
Full time employees 225 | Website https://www.fibrogen.com | ||
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.